Eledon Pharmaceuticals Overview
- Year Founded
-
2004
- Status
-
Public
- Employees
-
33
- Stock Symbol
-
ELDN
- Investments
-
3
- Share Price
-
$2.37
- (As of Thursday Closing)
Eledon Pharmaceuticals General Information
Description
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
Contact Information
Website
www.eledon.comCorporate Office
- 19800 MacArthur Boulevard
- Suite 250
- Irvine, CA 92612
- United States
Corporate Office
- 19800 MacArthur Boulevard
- Suite 250
- Irvine, CA 92612
- United States
Eledon Pharmaceuticals Timeline
Eledon Pharmaceuticals Stock Performance
As of 12-Nov-2026, Eledon Pharmaceuticals’s stock price is $2.37. Its current market cap is $200M with 84.5M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.37 | $2.67 | $1.35 - $4.49 | $200M | 84.5M | 905K | -$0.90 |
Eledon Pharmaceuticals Financials Summary
As of 30-Jun-2026, Eledon Pharmaceuticals has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 249,280 | 83,257 | 168,436 | (15,573) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (98,526) | (45,269) | (35,394) | (116,163) |
| Net Income | (98,561) | (45,617) | (36,184) | (116,537) |
| Total Assets | 126,094 | 169,009 | 177,405 | 89,066 |
| Total Debt | 467 | 641 | 954 | 383 |
Eledon Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Eledon Pharmaceuticals Comparisons
Industry
Financing
Details
Eledon Pharmaceuticals Competitors (19)
One of Eledon Pharmaceuticals’s 19 competitors is Gilead, a Formerly VC-backed company based in Foster City, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Gilead | Formerly VC-backed | Foster City, CA | ||||
| Ionis Pharmaceuticals | Corporate Backed or Acquired | Carlsbad, CA | ||||
| Astellas Pharma | Corporation | Tokyo, Japan | ||||
| Coherus Oncology | Formerly VC-backed | Redwood City, CA | ||||
| Amgen | Formerly PE-Backed | Thousand Oaks, CA |
Eledon Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Eledon Pharmaceuticals Patents
Eledon Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025235683-A1 | Methods and compositions for prevention of transplant rejection | Pending | 07-May-2024 | ||
| WO-2025235683-A9 | Methods and compositions for prevention of transplant rejection | Pending | 07-May-2024 | ||
| WO-2025235670-A1 | Use of anti-cd40 ligand antibodies for immunosuppression in islet cell transplantation | Pending | 07-May-2024 | ||
| AU-2024388148-A1 | Methods and compositions for prevention of transplant rejection | Pending | 28-Nov-2023 | ||
| EP-4816402-A1 | Methods and compositions for prevention of transplant rejection | Pending | 28-Nov-2023 | C07K16/2875 |
Eledon Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Eledon Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Eledon Pharmaceuticals Acquisitions (3)
Eledon Pharmaceuticals’s most recent deal was a Merger/Acquisition with Anelixis Therapeutics for . The deal was made on 14-Sep-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Anelixis Therapeutics | 14-Sep-2020 | Merger/Acquisition | Drug Discovery | ||
| Tokai Pharmaceuticals | 10-May-2017 | Merger/Acquisition | Pharmaceuticals | ||
| Protea Vaccine Technologies | 01-Dec-2008 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology |
Eledon Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
36.94 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Eledon Pharmaceuticals FAQs
-
When was Eledon Pharmaceuticals founded?
Eledon Pharmaceuticals was founded in 2004.
-
Where is Eledon Pharmaceuticals headquartered?
Eledon Pharmaceuticals is headquartered in Irvine, CA.
-
What is the size of Eledon Pharmaceuticals?
Eledon Pharmaceuticals has 33 total employees.
-
What industry is Eledon Pharmaceuticals in?
Eledon Pharmaceuticals’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is Eledon Pharmaceuticals a private or public company?
Eledon Pharmaceuticals is a Public company.
-
What is Eledon Pharmaceuticals’s stock symbol?
The ticker symbol for Eledon Pharmaceuticals is ELDN.
-
What is the current stock price of Eledon Pharmaceuticals?
As of 12-Nov-2026 the stock price of Eledon Pharmaceuticals is $2.37.
-
What is the current market cap of Eledon Pharmaceuticals?
The current market capitalization of Eledon Pharmaceuticals is $200M.
-
Who are Eledon Pharmaceuticals’s competitors?
Gilead, Ionis Pharmaceuticals, Astellas Pharma, Coherus Oncology, and Amgen are some of the 19 competitors of Eledon Pharmaceuticals.
-
What is Eledon Pharmaceuticals’s annual earnings per share (EPS)?
Eledon Pharmaceuticals’s EPS for 12 months was -$0.90.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
